In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Steve Fruchtman, President and CEO of Onconova Therapeutics Inc, about how the reallocation of resources within cancer centres around the world due to COVID-19. Steve talked us through the impacts on their early and late stage lead programs which includes short term restrictions such as accessing review data, as well as longer-term impacts including additional monitoring and testing for patients on haematology and oncology trials. Steve gives an insight into how they’re preparing for commercialization of their therapies within China, the affect COVID-19 has had on these partnerships, and how regulatory restrictions and language barriers can present a challenge in this area. Hosted on Acast. See acast.com/privacy for more information.